Literature DB >> 20182460

JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5.

C Cleyrat, J Jelinek, F Girodon, M Boissinot, T Ponge, J-L Harousseau, J-P Issa, S Hermouet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20182460     DOI： 10.1038/leu.2010.23

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?

Authors:  Sylvie Hermouet; Mathias Vilaine
Journal:  Haematologica       Date:  2011-11       Impact factor: 9.941

2.  Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics.

Authors:  Stephen E Langabeer
Journal:  JAKSTAT       Date:  2016-11-14

3.  Germline JAK2 L611S mutation in a child with thrombocytosis.

Authors:  Bernard Aral; Martine Courtois; Sylviane Ragot; Valentin Bourgeois; Elodie Bottolier-Lemallaz; Claire Briandet; François Girodon
Journal:  Haematologica       Date:  2018-03-22       Impact factor: 9.941

4.  Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.

Authors:  Daniela Pietra; Angela Brisci; Elisa Rumi; Sabrina Boggi; Chiara Elena; Alessandro Pietrelli; Roberta Bordoni; Maurizio Ferrari; Francesco Passamonti; Gianluca De Bellis; Laura Cremonesi; Mario Cazzola
Journal:  Haematologica       Date:  2011-01-12       Impact factor: 9.941

5.  Mpl traffics to the cell surface through conventional and unconventional routes.

Authors:  Cédric Cleyrat; Anza Darehshouri; Mara P Steinkamp; Mathias Vilaine; Daniela Boassa; Mark H Ellisman; Sylvie Hermouet; Bridget S Wilson
Journal:  Traffic       Date:  2014-07-18       Impact factor: 6.215

Review 6.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

Authors:  A Tefferi
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

7.  Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.

Authors:  Bin Li; Guangsen Zhang; Cui Li; Dan He; Xinying Li; Chunfang Zhang; Faqing Tang; Xiyun Deng; Jingchen Lu; Youhong Tang; Ruijuan Li; Zhuchu Chen; Chaojun Duan
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

Review 8.  The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?

Authors:  Marjorie Boissinot; Mathias Vilaine; Sylvie Hermouet
Journal:  Cancers (Basel)       Date:  2014-08-12       Impact factor: 6.639

9.  Myelodysplastic Syndrome/Acute Myeloid Leukemia Arising in Idiopathic Erythrocytosis.

Authors:  Stephen E Langabeer; Eibhlin Conneally; Catherine M Flynn
Journal:  Case Rep Hematol       Date:  2018-02-22

Review 10.  Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation.

Authors:  Sylvie Hermouet; Edith Bigot-Corbel; Betty Gardie
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.